Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study-Reference-Cited by-同舟云学术

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study

Published:2020-11-10 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Zhao Shen,Zhang Zhen,Fang Wenfeng,Zhang Yaxiong,Zhang Zhonghan,Hong Shaodong,Ma Yuxiang,Zhou Ting,Yang Yunpeng,Huang Yan,Zhao Hongyun,Zhang Li

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference27 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. Gefitinib or chemotherapy for non–smallcell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

5. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spindle Cell Lesions with Oncogenic EGFR Kinase Domain Aberrations: Expanding the Spectrum of Protein Kinase–Related Mesenchymal Tumors;Modern Pathology;2024-09

2. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications;Cells;2023-12-25

3. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature;Expert Opinion on Drug Metabolism & Toxicology;2021-07-03